Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Abbott Laboratories

Evaluate

July 05, 2023

Medtech dealmaking grinds almost to a halt

M&A moves are down, venture rounds few and IPOs nonexistent.

Thumbnail
May 22, 2023

Clearance makes Beta Bionics look like a target

Article image
Vantage logo
April 24, 2023

Medtronic plays catch-up in diabetes

The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.

Article image
Vantage logo
April 24, 2023

Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation

The group is fast developing its new atrial fibrillation devices. But will it be fast enough?

Article image
Vantage logo
February 09, 2023

Abbott goes peripheral for $890m

Article image
Vantage logo
January 13, 2023

Medtech approvals stagnate

Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.

Article image
Vantage logo
January 11, 2023

Few big bangs in a quiet year for medtech mergers

J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.

Article image
Vantage logo
December 09, 2022

Medtronic left behind by the new class of glucose monitors

Article image
Vantage logo
November 18, 2022

Big medtechs’ efficiency starts to recover from Covid

Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.

Article image
Vantage logo
October 14, 2022

Medtech bleeds corporate venture cash

Overall venture investment in the sector remains steady, but the big strategics back off.

Article image
Vantage logo
September 20, 2022

TCT 2022 – Edwards tries to Clasp an opportunity

The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up